Cargando…

Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension

BACKGROUND: Pulmonary hypertension (PH) remains a prevalent disease globally. Sodium tanshinone II sulfonate A (STS) has been used in clinical treatment of PH. AIMS: The aim of the present study was to investigate the effect of sodium STS treatment on hypoxia-induced PH and related mechanisms. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Ya-Ru, Chen, Jing-Wei, Jiang, Yan, Wang, Lin-Hui, Xue, Rong, Qian, Jin-Xian, Zhang, Guo-Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253651/
https://www.ncbi.nlm.nih.gov/pubmed/32508639
http://dx.doi.org/10.3389/fphar.2020.00687
_version_ 1783539374576631808
author Bao, Ya-Ru
Chen, Jing-Wei
Jiang, Yan
Wang, Lin-Hui
Xue, Rong
Qian, Jin-Xian
Zhang, Guo-Xing
author_facet Bao, Ya-Ru
Chen, Jing-Wei
Jiang, Yan
Wang, Lin-Hui
Xue, Rong
Qian, Jin-Xian
Zhang, Guo-Xing
author_sort Bao, Ya-Ru
collection PubMed
description BACKGROUND: Pulmonary hypertension (PH) remains a prevalent disease globally. Sodium tanshinone II sulfonate A (STS) has been used in clinical treatment of PH. AIMS: The aim of the present study was to investigate the effect of sodium STS treatment on hypoxia-induced PH and related mechanisms. METHODS: Male Sprague-Dawley rats were housed in a hypoxic chamber with an oxygen concentration of 10 ± 1% for 8 h a day over 21 days. Rats were treated with either STS (low-dose: 10 mg/kg or high-dose: 30 mg/kg) or LY294002 (which is an inhibitor of PI3K). Pulmonary arterial pressure (PAP) was measured, right ventricular hypertrophy parameters were monitored, lung edema parameters were measured, and pathological changes were observed by hematoxylin-eosin (HE) staining. Protein expressions of apoptosis, and PI3K/AKT/mTOR/autophagy pathways in rat lung tissue were examined by western blot. Levels of the pro-inflammatory factors IL-6, IL-8, TNF-α in lung tissues of rats were measured using an enzyme linked immunosorbent assay (ELISA). RESULTS: Results of our study demonstrate that persistent exposure to hypoxic conditions increased PAP, right ventricular hypertrophy, lung edema, parameters of lung vascular proliferation and decreased the ratio of Bax/Bcl-2. Furthermore, hypoxic conditions activated the PI3K/Akt/mTOR pathway, inhibited autophagy, and elevated abundance of inflammatory factors in rat lung tissue. Treatment with STS resulted in a dose-dependent decrease in PAP, right ventricular hypertrophy, lung edema, lung vascular proliferation and reversed hypoxia induced lung tissue protein expression and pro-inflammatory factors in rat lung tissue. In addition, hypoxia-induced increases in PAP, cardiac hypertrophy, and lung expression of the proteins PI3K/Akt/mTOR/autophagy pathway were partially reversed by treatment with LY294002. CONCLUSIONS: STS alleviates hypoxia-induced PH by promoting apoptosis, inhibiting PI3K/AKT/mTOR pathway, up-regulating autophagy, and inhibiting inflammatory responses.
format Online
Article
Text
id pubmed-7253651
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72536512020-06-05 Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension Bao, Ya-Ru Chen, Jing-Wei Jiang, Yan Wang, Lin-Hui Xue, Rong Qian, Jin-Xian Zhang, Guo-Xing Front Pharmacol Pharmacology BACKGROUND: Pulmonary hypertension (PH) remains a prevalent disease globally. Sodium tanshinone II sulfonate A (STS) has been used in clinical treatment of PH. AIMS: The aim of the present study was to investigate the effect of sodium STS treatment on hypoxia-induced PH and related mechanisms. METHODS: Male Sprague-Dawley rats were housed in a hypoxic chamber with an oxygen concentration of 10 ± 1% for 8 h a day over 21 days. Rats were treated with either STS (low-dose: 10 mg/kg or high-dose: 30 mg/kg) or LY294002 (which is an inhibitor of PI3K). Pulmonary arterial pressure (PAP) was measured, right ventricular hypertrophy parameters were monitored, lung edema parameters were measured, and pathological changes were observed by hematoxylin-eosin (HE) staining. Protein expressions of apoptosis, and PI3K/AKT/mTOR/autophagy pathways in rat lung tissue were examined by western blot. Levels of the pro-inflammatory factors IL-6, IL-8, TNF-α in lung tissues of rats were measured using an enzyme linked immunosorbent assay (ELISA). RESULTS: Results of our study demonstrate that persistent exposure to hypoxic conditions increased PAP, right ventricular hypertrophy, lung edema, parameters of lung vascular proliferation and decreased the ratio of Bax/Bcl-2. Furthermore, hypoxic conditions activated the PI3K/Akt/mTOR pathway, inhibited autophagy, and elevated abundance of inflammatory factors in rat lung tissue. Treatment with STS resulted in a dose-dependent decrease in PAP, right ventricular hypertrophy, lung edema, lung vascular proliferation and reversed hypoxia induced lung tissue protein expression and pro-inflammatory factors in rat lung tissue. In addition, hypoxia-induced increases in PAP, cardiac hypertrophy, and lung expression of the proteins PI3K/Akt/mTOR/autophagy pathway were partially reversed by treatment with LY294002. CONCLUSIONS: STS alleviates hypoxia-induced PH by promoting apoptosis, inhibiting PI3K/AKT/mTOR pathway, up-regulating autophagy, and inhibiting inflammatory responses. Frontiers Media S.A. 2020-05-21 /pmc/articles/PMC7253651/ /pubmed/32508639 http://dx.doi.org/10.3389/fphar.2020.00687 Text en Copyright © 2020 Bao, Chen, Jiang, Wang, Xue, Qian and Zhang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Bao, Ya-Ru
Chen, Jing-Wei
Jiang, Yan
Wang, Lin-Hui
Xue, Rong
Qian, Jin-Xian
Zhang, Guo-Xing
Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension
title Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension
title_full Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension
title_fullStr Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension
title_full_unstemmed Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension
title_short Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension
title_sort sodium tanshinone ii sulfonate a ameliorates hypoxia-induced pulmonary hypertension
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253651/
https://www.ncbi.nlm.nih.gov/pubmed/32508639
http://dx.doi.org/10.3389/fphar.2020.00687
work_keys_str_mv AT baoyaru sodiumtanshinoneiisulfonateaameliorateshypoxiainducedpulmonaryhypertension
AT chenjingwei sodiumtanshinoneiisulfonateaameliorateshypoxiainducedpulmonaryhypertension
AT jiangyan sodiumtanshinoneiisulfonateaameliorateshypoxiainducedpulmonaryhypertension
AT wanglinhui sodiumtanshinoneiisulfonateaameliorateshypoxiainducedpulmonaryhypertension
AT xuerong sodiumtanshinoneiisulfonateaameliorateshypoxiainducedpulmonaryhypertension
AT qianjinxian sodiumtanshinoneiisulfonateaameliorateshypoxiainducedpulmonaryhypertension
AT zhangguoxing sodiumtanshinoneiisulfonateaameliorateshypoxiainducedpulmonaryhypertension